Patients with Guillain-Barré syndrome with a poor prognosis do not benefit from a second intravenous immunoglobulin dose, according to a study published in The Lancet Neurology.
The first phase 3 trial comparing ponesimod to teriflunomide found ponesimod to be more effective at reducing the annualized relapse rate in multiple sclerosis (MS) patients.
The US Food and Drug Administration has recently approved ponesimod, an oral treatment, for adults with relapsing multiple sclerosis.
Onasemnogene abeparvovec yielded clinically meaningful responses and a favorable benefit-risk profile for patients with spinal muscular atrophy type 1, according to findings from a recent phase 3 trial.
Quality of life outcomes improved for patients treated with endovascular therapy 6 to 16 hours after stroke versus standard therapy alone, according to secondary analysis of the DEFUSE 3 randomized clinical trial.
Early findings suggest donanemab may slow cognitive decline in patients with early Alzheimer’s disease, according to results of a randomized, phase 2 trial.
Recent findings suggest that prehospital administration of tranexamic acid could lead to increased mortality in patients with isolated severe traumatic brain injury.
The US Food and Drug Administration has cleared a novel device to be worn around the neck among athletes aged 13 years or older to help protect the brain from the consequences of repeated subconcussive impacts to the head.
In a bidirectional Mendelian randomization study, researchers used recent genome-wide association study data to further examine the relationship between multiple sclerosis and depression.
On October 17 to 19, 2021, our partner, the American Neurological Association, will host its second interactive, virtual meeting experience. The reimagined program builds on the success of last year’s first-ever Virtual Annual Meeting and as always, will explore the latest advances in translational neuroscience, neurobiology of disease and academic neurology.